BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8735336)

  • 1. Prognostic variables and survival in pediatric acute lymphoblastic leukemias: cancer institute experience.
    Shanta V; Maitreyan V; Sagar TG; Gajalakshmi CK; Rajalekshmy KR
    Pediatr Hematol Oncol; 1996; 13(3):205-16. PubMed ID: 8735336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia.
    Visser JH; Wessels G; Hesseling PB; Louw I; Oberholster E; Mansvelt EP
    Pediatr Hematol Oncol; 2001; 18(3):187-91. PubMed ID: 11293286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment results in children with standard-risk acute lymphoblastic leukemia. Report of the Polish Pediatric Leukemia/Lymphoma Study Group].
    Derwich K; Kaczmarek-Kanold M; Wachowiak J; Balcerska A; Balwierz W; Chybicka A; Kowalczyk JR; Matysiak M; Sońta-Jakimczyk D; Wysocki M; Chełmecka-Hanuszewicz L; Jackowska T; Kołtan A; Cwiklińska M; Odój T; Płoszyńska A; Steczowicz M; Wojciechowska V; Wójtowicz A
    Przegl Lek; 2004; 61 Suppl 2():49-52. PubMed ID: 15686046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
    Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
    Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
    Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
    Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
    Yetgin S; Cetin M
    Leuk Lymphoma; 2003 Mar; 44(3):489-95. PubMed ID: 12688320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
    Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult acute lymphoblastic leukemia: results of an aggressive regimen in India.
    Raje N; Pai S; Vaidya S; Gopal R; Parikh P; Saikia T; Pai V; Nadkarni K; Advani IM
    Leuk Lymphoma; 1994 Jul; 14(3-4):285-90. PubMed ID: 7950917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
    Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
    Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
    Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group Study.
    van Eys J; Berry D; Crist W; Doering E; Fernbach D; Pullen J; Shuster J; Wharam M
    Cancer; 1989 Jan; 63(1):23-9. PubMed ID: 2910421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
    Bowman WP; Larsen EL; Devidas M; Linda SB; Blach L; Carroll AJ; Carroll WL; Pullen DJ; Shuster J; Willman CL; Winick N; Camitta BM; Hunger SP; Borowitz MJ
    Pediatr Blood Cancer; 2011 Oct; 57(4):569-77. PubMed ID: 21360654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type].
    López-Hernández MA; Alvarado-Ibarra M; Álvarez-Veral JL; Ortiz-Zepeda M; Guajardo-Leal ML; Cota-Range X
    Gac Med Mex; 2016; 152(5):439-443. PubMed ID: 27792701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
    Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
    Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
    Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
    Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
    Pedrosa F; Coustan-Smith E; Zhou Y; Cheng C; Pedrosa A; Lins MM; Pedrosa M; Lucena-Silva N; Ramos AML; Vinhas E; Rivera GK; Campana D; Ribeiro RC
    Blood; 2020 Apr; 135(17):1458-1466. PubMed ID: 32027741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute lymphoblastic leukemia in children: nonrandomized comparison of conventional vs. intensive chemotherapy at the National Cancer Institute of Colombia.
    Buendia MT; Terselich G; Lozano JM; Viscaino MP
    Med Pediatr Oncol; 1997 Feb; 28(2):108-16. PubMed ID: 8986146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol.
    Gaiger A; Linnerth B; Mann G; Schmid D; Heinze G; Tisljar K; Haas OA; Gadner H; Lion T
    Eur J Haematol; 1999 Aug; 63(2):86-93. PubMed ID: 10480287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.